HPV Vaccine Information Sheet
Total Page：16
File Type：pdf, Size：1020Kb
INFORMATION SHEET OBSERVED RATE OF VACCINE REACTIONS Global Vaccine safety Essential Medicines & Health Products HUMAN PAPILLOMA VIRUS VACCINE 20, Avenue Appia, Ch- 1211 Geneva 27 December 2017 Types of vaccines an adjuvant. The available vaccines differ in the number of HPV genotypes that they Currently available HPV vaccines consist of contain, the way that they are manufactured recombinant viral vaccine proteins containing and the adjuvant that they contain. Both 2v- highly purified virus-like particles (VLP) which HPV and 4v-HPV vaccines are highly are the protein shells of the HPV virus (major immunogenic and prevent primary infection capsid protein L1). The VLP contain no viral with the HPV genotypes and prevent CIN 2/3 DNA. Thus, they cannot infect cells, reproduce adenocarcinoma. Pre-licensure trials indicate or cause disease. The VLP for each virus a broadly similar safety profile for minor and genotype are purified and then adsorbed onto severe adverse events for each of the vaccines. (See table 1) Table 1 Name Vaccine antigens Excipients Gardasil 4v 4v-HPV Produced in recombinant S. cerevisiea VLP from genotypes 6, culture. Aluminum hydroxyphosphate, Polysorbate 80, sodium 11, 16, 18 borate and L Histidine Gardasil 9v 9v-HPV Produced using recombinant Saccharomyces cerevisiae. VLP from genotypes 6, Aluminium (provided as AAHS), sodium chloride, L- 11, 16, 18, 31, 33, 45, histidine, polysorbate 80, sodium Borate and yeast 52, and 58 protein. Does not contain preservative or antibiotics. Cervarix 2v 2v-HPV Produced in recombinant Baculovirus expression vector VLP from genotypes system. Aluminum hydroxide plus deacylated 16, 18 onophosphoryl l ipid A used as an adjuvant (AS04) Safety summary and information sheet (GACVS) who have not identified any safety concerns As at June 2017 it is estimated that over 270 http://www.who.int/vaccine_safety/committ million doses of the HPV vaccine have been ee/topics/hpv/en/ distributed. Post-licensure surveillance data concerning the safety profiles for each of the This HPV information sheet was adapted from HPV vaccine brands have detected no serious the earlier version first published in June 2012 safety issues to date except rare reports of following a systematic literature review, anaphylaxis. The safety of the HPV vaccine has conducted in December 2016, which included been regularly reviewed by the Global available evidence on the serious adverse Advisory Committee for Vaccine Safety events associated with HPV vaccines. A large body of randomised controlled trial Systemic adverse events evidence comprising 72,835 subjects provided data upon which the rates of serious adverse In clinical trials prior to licensure of the 4v- events were calculated. In addition, several HPV vaccine, systemic adverse events were monitored for the first 15 days post large cohort studies provided evidence for specific health outcomes, predominantly vaccination. The only adverse event reported autoimmune diseases. The specific that occurred in greater than 1% of vaccines and occurred more frequently than placebo methodology, articles’ profiles and quality of evidence that compromise the systematic was pyrexia (10.1 versus 8.4% according to review can be accessed through EMEA CHMP (2006), respectively). http://www.who.int/vaccine_safety/HPV_vac A number of other systemic adverse events, cination_safety_report_AHTA_dec17.pdf of minor nature were reported, but these occurred with less than a 0.5% difference in the vaccinated group. Mild systemic adverse Adverse events events possibly related to vaccination included headache, dizziness, myalgia, Minor adverse events (See table 2) arthralgia, and gastrointestinal symptoms (nausea, vomiting abdominal pain). In a direct Local adverse events comparison of the 2v-HPV and 4v-HPV The 9v-HPV vaccine was well-tolerated, and vaccines, systemic reactions were reported at most adverse events were injection site- comparable rates, with the exception of related pain, swelling, and erythema that fatigue [49.8% (95% CI: 45.5-54.2) vs. 39.8% were mild to moderate in intensity. The safety (35.6-44.1)] and myalgia [27.6% (95% CI: 23.8- profiles were similar in 4v-HPV and 9v-HPV 31.6) vs. 19.6% (16.3-23.3)], which were vaccinees. Among females aged 9 through 26 reported more frequently amongst recipients years, 9vHPV recipients had more injection- of the 2v-HPV vaccine. (See table 2) site adverse events, including swelling (40.3% in the 9vHPV group compared with 29.1% in the 4v-HPV group) and erythema (34.0% in Severe or serious adverse events – the 9vHPV group compared with 25.8% in the systematic review (See table 3) 4v-HPV group). Males had fewer injection site adverse events. In males aged 9 through 15 This comprehensive systematic review years, injection site swelling and erythema in containing a large body of high-level evidence 9vHPV recipients occurred in 26.9% and is very consistent in finding no evidence of 24.9%, respectively. Rates of injection-site severe or serious adverse events associated swelling and erythema both increased with difference in the rate of Serious Adverse following each successive dose of 9vHPV. (See Events (SAE) between people who have table 2) received either the 2v-HPV or 4v-HPVvaccines https://www.cdc.gov/mmwr/preview/mmwrh and people who received a placebo or a tml/mm6411a3.htm control vaccine. Good quality cohort studies of specific autoimmune and other SAEs also found no relationship between exposure to HPV vaccination and development of these outcomes. 2 The results of the analysis for the specific independent of immunisation and their outcomes are summarised in the Summary of pathogenesis is poorly understood. Their Findings Table using the Grading of causal association with immunization is not Recommendations, Assessment, Development established. However, it is plausible that CRPS and Evaluation (GRADE) methodology may occur in a limb that has been the site of http://www.gradeworkinggroup.org/. an injected vaccine as other causes of local trauma may trigger this condition. CRPS has These outcomes included SAE, new onset been described, in case reports, to present chronic disease and medically significant soon after immunisation. The association conditions. A comparison of effects show that between POTS and CRPS has been reviewed there is no absolute event rate difference for by the European Medicines Agency (EMA) any of these conditions in those vaccinated who have concluded that there is no causal with HPV vaccine (2v-HPV or 4v-HPV) and association between these conditions and placebo (or those vaccinated with a control HPV immunization. vaccine). For auto-immune disease, venous thromboembolism, multiple sclerosis and Death Deaths were reported in nearly every other demyelinating conditions safety data is study, and the number of deaths was very low. available from high quality cohort studies No death was considered vaccine related in which have not demonstrated differences in the Gardasil studies, and two of the Cervarix the rates of these conditions in those exposed studies reported the causes of death without or unexposed to the HPV vaccine. Rare or very commenting their causality. rare adverse events (such as auto-immunity) can only be evaluated for safety using post- HPV vaccine in combination with other licensure surveillance studies because vaccines. Assessment of concomitant use of randomised controlled trials do not have the 4v-HPV vaccine and recombinant Hepatitis B vaccine showed no increase in adverse adequate power to detect such events. events. Concomitant use of the 2v-HPV The current estimated rate of anaphylaxis is vaccine with combined diphtheria-tetanus- 1.7 cases per million doses. This is consistent acellular pertussis-inactivated poliovirus with the rate of anaphylaxis following other vaccine to girls and young women was vaccines. The rates for anaphylaxis for other generally well tolerated. vaccines given to children and adolescents range from 0 to 3.5 per million doses in HPV vaccine in pregnancy. In the absence of international studies which have used well-controlled studies in pregnant women, vaccination with HPV vaccine is not different case definitions for anaphylaxis. recommended in pregnancy as a precautionary measure. However, some data is available because pregnant women have Other vaccine safety issues been enrolled in phase III clinical trials with known pregnancy outcomes and through the Postural Orthostatic Tachycardia Syndrome establishment of pregnancy registers. In a (POTS), Chronic Regional Pain Syndrome combined analysis of pregnancy outcomes for (CRPS), Chronic Fatigue Syndrome (CFS). POTS, women aged up to 45 years, the CRPS, and CFS are reported as adverse events administration of 4v-HPV human following HPV immunization. These papillomavirus vaccine to women who conditions most commonly occur became pregnant during the phase III clinical 3 trials did not appear to negatively affect For the reviews of serious adverse events, pregnancy outcomes. A pooled analysis of two academics who specialize in systematic randomized controlled trials on the risk of literature reviews and assessment of evidence miscarriage with 2v-HPV vaccine provided no quality using the GRADE process have been evidence overall for an association between contracted. This material is then reviewed by HPV vaccination and risk of miscarriage. Of GACVS (or a GACVS subcommittee) and also 517 reports of pregnancies enrolled on a by the WHO Immunization, Vaccines and register, rates of spontaneous abortions and Biologicals division. GACVS approves the major birth defects were not greater than material before review by the WHO Assistant those in the unexposed population. An Director General’s office. analysis of phase III trials and post-marketing Publications of the WHO vaccine reaction data identifying reports of 90 pregnancies within 30 days of vaccination showed no rates information sheets can be found at increased risk of spontaneous abortion, fetal http://www.who.int/vaccine_safety/initiative malformations, or adverse pregnancy /tools/vaccinfosheets/en/. Information sheets outcomes in the general population. are periodically reviewed on a need based manner with newer vaccines being more Syncope in adolescent girls.